Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. - Juhl,CB.; Hollingdal,M.; Sturis,J.; Jakobsen,G.; Agerso,H.; Veldhuis,J.; Porksen,N.; Schmitz,O. (Diabetes, 2002)